• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Poll: How comfortable are you with including biosimilars in your treatment plans?

Poll

Vote in our most recent poll!

How comfortable are you with including biosimilars in your treatment plans?

A. Very excited to begin embracing biosimilars
B. Feeling comfortable exploring biosimilar options, though cautiously
C. Still hesitant, I need to learn more about biosimilars
D. With the knowledge of biosimilars I have, I am not comfortable including this in my treatment plans

RELATED: Introduction to biosimilars for AMD

Related Videos
Emily Chew, MD, outlines her lecture that landed her the Proctor Award at ARVO 2024
Deborah Ferrington details a session on mitochondrial maintenance and retinal health in patients with AMD at ARVO 2024
R Tracy Williams, OD, FAAO with Optometry Times
Robert Weiss, former CEO and President of The Cooper Companies, Inc. (left) and Optometry Times' Assistant Managing Editor Emily Kaiser Maharjan Image Credit ©Optometry Times
Jeffrey J. Walline, OD, PhD
Easy Anyama
© 2024 MJH Life Sciences

All rights reserved.